CORDIS
EU research results

CORDIS

English EN
Epigenetic plasticity of the Genome

Epigenetic plasticity of the Genome

Objective

In this 'post-genomic' era, advances in epigenetic research represent a new frontier that is predicted to yield novel insights for gene regulation, cell differentiation, stem cell plasticity, organismal development, human diseases, cancer, infertility and aging. A central emerging concept proposes that there is an 'epigenetic code', which considerably extends the information potential of the genetic code. Thus, one genome can generate many 'epigenomes' as the fertilised egg progresses through development and translates its information into a multitude of cell fates. Research into epigenetics touches on many topics of key interest to the general public, including embryonic and adult stem cells, and is anticipated to have far-reaching implications for medicine and the understanding of the basic processes of cell fate determination. The resulting developments will undoubtedly impact academic and industrial research communities and will form an important knowledge base for policy makers and public bodies that contribute to the socio-economic future of our 'post-genomic' society. Europe has many world leading laboratories in epigenetic research. This network of excellence proposes to follow a progressively expanding strategy. For its initial establishment, 24 teams with a proven record as leaders in their field, will constitute a 'virtual core centre' to combine their expertise and resources. An immediate structuring role is provided by the concentration of these 24 teams around 8 established centres of epigenetic research. In defining a coordinated joint programme of activities, this NoE will assimilate existing synergies for building a structure that can feed three important needs: to advance scientific discoveries, integrate European research and establish an open dialogue. To achieve these three goals, the core NoE will make £ 50% of the grant available for network development and the durable shaping of a coherent European Research #'

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FORSCHUNGSINSTITUT FÜR MOLEKULARE PATHOLOGIE GES.M.B.H.

Address

Dr. Bohr-Gasse 7
Vienna

Austria

Administrative Contact

Meinrad BUSSLINGER (Professor)

Participants (29)

Sort alphabetically

Expand all

RUPRECHT-KARLS-UNIVERSITY HEIDELBERG

Germany

DEUTSCHES KREBSFORSCHUNGSZENTRUM

Germany

SAARLAND UNIVERSITY

Germany

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

ERASMUS MEDICAL CENTER ROTTERDAM

Netherlands

THE UNIVERSITY OF EDINBURGH

United Kingdom

MEDICAL RESEARCH COUNCIL

United Kingdom

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

THE CHANCELLOR, MASTERS & SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

UNIVERSITY OF LEEDS

United Kingdom

INSTITUT CURIE AND CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

INSTITUT PASTEUR

France

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

KAROLINSKA INSTITUTET

Sweden

INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE

France

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands

FONDAZIONE TELETHON

Italy

NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH

Switzerland

INSTITUTE OF MOLECULAR BIOTECHNOLOGY GMBH

Austria

MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

Germany

CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GES.M.B.H.

Austria

EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRICH

Switzerland

FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III

Spain

GMI - GREGOR MENDEL INSTITUT FÜR MOLEKULARE PFLANZENBIOLOGIE GMBH

Austria

INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE

France

MARTIN-LUTHER-UNIVERSITÄT HALLE-WITTENBERG

Germany

UNIVERSITY OF ZÜRICH

Switzerland

UNIVERSITÉ DE GENÈVE

Switzerland

Project information

Grant agreement ID: 503433

  • Start date

    1 June 2004

  • End date

    31 May 2010

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 22 270 000

  • EU contribution

    € 12 500 000

Coordinated by:

FORSCHUNGSINSTITUT FÜR MOLEKULARE PATHOLOGIE GES.M.B.H.

Austria